

**Fig. 4.** (A) TRIM5 $\alpha$  protein lysates of MT4 and CEM-SS cells infected with recombinant SeV expressing CBC, CBB, 111 (Rh), or 222 (CM) were visualized by Western blotting with antibodies against HA tag and actin. The relative TRIM5 $\alpha$  expression obtained from the band intensity of TRIM5 $\alpha$  divided by that of actin is shown. (B) CEM-SS cells were infected with recombinant SeV expressing CBC (■), CBB (□), 111 (Rh) (●), 222 (CM) (○), or CM.SPRY(-) (\*) TRIM5 $\alpha$ . Nine hours after infection, cells were superinfected with HIV-2 GH123, or HIV-2 GH123/Q viruses. Culture supernatants were separately assayed for levels of p25. Error bars show actual fluctuations between levels of p25 in duplicate samples. A representative of three independent experiments is shown.

acid residue P at the 385th position was replaced with S (CBB P385S TRIM5 $\alpha$ ; Fig. 2A) and compared its ability to restrict HIV-2 GH123/Q with that of CBB TRIM5 $\alpha$ . As expected, CBB P385S TRIM5 $\alpha$  could inhibit HIV-2 GH123/Q replication to a larger extent than CBB chimeric TRIM5 $\alpha$  did (Fig. 3C right) ( $p < 0.00005$ ,  $t$ -test,  $n = 4$ ). This finding shows that a single amino acid substitution from P to S at the 385th position of baboon TRIM5 $\alpha$  strengthens its anti-HIV-2 activity.

#### A. single amino acid in V2 of the SPRY domain of TRIM5 $\alpha$ affects its restriction activity against HIV-2

Cynomolgus monkey TRIM5 $\alpha$  has S at the 383rd amino acid position, which corresponds to the 385th amino acid of baboon and rhesus monkey TRIM5 $\alpha$ s (Fig. 1 box). To know whether an S-to-P amino acid substitution at the 385th or 383rd position also affects anti-HIV-2 activity of rhesus or cynomolgus monkey TRIM5 $\alpha$ , we constructed SeVs expressing mutant rhesus monkey TRIM5 $\alpha$  with amino acid residue S at the 385th position replaced with P (Rh S385P TRIM5 $\alpha$ ) and mutant cynomolgus monkey TRIM5 $\alpha$  with S at the 383rd position replaced with P (CM S383P TRIM5 $\alpha$ ) (Fig. 2A). These mutant TRIM5 $\alpha$ s were expressed at levels similar to those of the wild type TRIM5 $\alpha$  (Fig. 2B). CM S383P TRIM5 $\alpha$  and the wild type cynomolgus monkey TRIM5 $\alpha$  restricted HIV-2 GH123 replication (Fig. 3D left), whereas they failed to restrict HIV-2 GH123/Q replication (Fig. 3D right). However, it should be noted that HIV-2

GH123 attained slightly higher titers on day 6 in cells expressing CM S383P TRIM5 $\alpha$  than in those expressing the wild type cynomolgus monkey TRIM5 $\alpha$  (Fig. 3D left). The difference was very small, but statistically significant in six independent samples ( $p < 0.0001$ ,  $t$ -test). In contrast, we could not detect any statistically significant differences in anti-HIV-2 activity between the wild type and mutant rhesus monkey TRIM5 $\alpha$ s in six independent samples (Fig. 3D). It is possible that the effects of small amino acid changes in V2 on anti-viral activity vary depending on differences in V1.

#### Chimeric TRIM5 $\alpha$ containing the baboon SPRY domain failed to restrict HIV-2 GH123/Q replication in human T cell line CEM-SS

After we obtained data presented in Fig. 3, we realized that the expression levels of TRIM5 $\alpha$  protein by SeVs are much lower in another T cell line CEM-SS than those in MT4 cells. To examine the restriction ability of chimeric TRIM5 $\alpha$ s with more physiological levels of expression, we repeated the experiment of Fig. 3A in CEM-SS cells. The expression levels of TRIM5 $\alpha$  compared to those of actin protein in CEM-SS cells were approximately one-fifth of those in MT4 cells (Fig. 4A). As shown in Fig. 4B, all TRIM5 $\alpha$ s inhibited HIV-2 GH123 replication, although the extent of inhibition varied among the TRIM5 $\alpha$ s. CBB chimeric TRIM5 $\alpha$  partially inhibited HIV-2 GH123 (Fig. 4B left) but failed to inhibit HIV-2 GH123/Q (Fig. 4B right) in CEM-SS cells. These findings demonstrate that chimeric TRIM5 $\alpha$  containing the baboon SPRY domain fails to restrict HIV-2 GH123/Q replication.




Fig. 5. (A) TRIM5 $\alpha$  protein lysates of CEM-SS cells infected with recombinant SeV expressing BBB, BBB P385S, CBB, or CBB P385S TRIM5 $\alpha$  were visualized by Western blotting with antibodies against HA tag and actin. (B) CEM-SS cells were infected with recombinant SeV expressing BBB (□), BBB P385S (■), CBB (○), CBB P385S (●), 111 (Rh) (◇), CM SPRY(-) (\*), or AGM TRIM5 $\alpha$  lacking coiled-coil domain (CC(-) TRIM5 $\alpha$ ) (Δ). Nine hours after infection, cells were superinfected with HIV-2 GH123, or HIV-2 GH123/Q viruses. Culture supernatants were separately assayed for levels of p25. Error bars show actual fluctuations between levels of p25 in duplicate samples. A representative of two independent experiments is shown.

#### The full-length baboon TRIM5 $\alpha$ also failed to restrict HIV-2 GH123/Q replication in CEM-SS cells

Finally, we constructed SeV expressing the full-length baboon TRIM5 $\alpha$  (BBB TRIM5 $\alpha$ ), and the mutant baboon TRIM5 $\alpha$  in which amino acid residue P at the 385th position was replaced with S (BBB P385S TRIM5 $\alpha$ ) to confirm the effect of the 385th amino acid in the full-length baboon TRIM5 $\alpha$ . Expression levels of BBB and BBB P385S TRIM5 $\alpha$ s were comparable to those of CBB and CBB P385S TRIM5 $\alpha$ s (Fig. 5A). Consistent with results presented in Fig. 4B, BBB TRIM5 $\alpha$  restricted HIV-2 GH123 (Fig. 5B left), but failed to restrict HIV-2 GH123/Q (Fig. 5B right) in CEM-SS cells. Anti-HIV-2 GH123 and GH123/Q activities of BBB and BBB P385S TRIM5 $\alpha$ s were comparable to those of CBB and CBB P385S TRIM5 $\alpha$ s, respectively (Fig. 5B). These results excluded the possibility that the RBCC domain of baboon TRIM5 $\alpha$  contains potency determinants for restriction of HIV-2. Furthermore, the difference in anti-HIV-2 GH123 and GH123/Q activity between BBB and BBB P385S TRIM5 $\alpha$  was also observed in CEM-SS cells (Fig. 5B right) ( $p < 0.01$ ,  $n = 4$ ,  $t$ -test) and MT4 cells (data not shown) confirming that a single amino acid at the 385th position of the baboon TRIM5 $\alpha$  affects its restriction activity against HIV-2. In Fig. 5B, there was no difference in the effects of HIV-2 GH123 and GH123/Q replication between CM SPRY(-) TRIM5 $\alpha$  and AGM TRIM5 $\alpha$  lacking coiled-coil domain (CC(-) TRIM5 $\alpha$ ). CM SPRY(-) TRIM5 $\alpha$  suppressed activity of endogenous TRIM5 $\alpha$ , while CC(-) TRIM5 $\alpha$  was a non-interfering mutant (Nakayama et al., 2006; Maegawa et al., 2008). Therefore, these results indicated that effects of endogenous TRIM5 $\alpha$  in CEM-SS cells could be neglected in our assay.

#### Structural model of the SPRY domain of baboon TRIM5 $\alpha$

To gain further insight into the structural effects of single amino acid substitution at the 385th position of the baboon SPRY domain, a three-dimensional (3-D) model of the baboon SPRY domain was constructed by a homology-modeling based on the recently published

crystal structure of the PRYSPRY domain of mouse TRIM21 (protein data bank (PDB) ID: 2VOK and 2VOL) (Keeble et al., 2008) and the human PRYSPRY-19q13.4.1 domain (PDB ID: 2FBE) (Gruetter et al., 2006). A previous study described the 3-D model of the SPRY domain of TRIM5 $\alpha$  based on the structure of the GUSTAVUS SPRY domain




Fig. 6. Structural model of the SPRY domain of baboon TRIM5 $\alpha$ . The 3-D model of the baboon SPRY domain was constructed with a homology-modeling technique using Modeller 9v4, and visualized with PyMol v1.0r2. The baboon SPRY model (green cartoon) is superimposed on the structure of the SPRY domain of mouse TRIM21 (orange backbone trace). Insertions in the baboon SPRY domain relative to the templates are shown in red, and V1, V2 and V3 in blue. The spheres indicate P at the 385th position in V2.

(PDB ID: 2FNJ) and 2FBE (Ohkura et al., 2006). The amino acid identity between the two more recently published SPRY domain structures (2VOK and 2VOL) and the SPRY domain of baboon TRIM5 $\alpha$  is 35% and is over 10% larger than the domain identity with the templates used in the previous studies. Thus, owing to the use of more similar templates, we expect our model to be more reliable. In our model (Fig. 6), V1 and V2 are located in the loops at the surface of the SPRY domain structure. Unfortunately, P residue at the 385th position in V2 was one of the four amino acid insertions of the baboon SPRY domain sequence as compared to the templates. However, as the insertion is short, we do not expect major errors in this region of the model, and we can assume that the insertion is located at the protein surface. In the model, V2 is located near V1, and P residue at the 385th position of baboon TRIM5 $\alpha$  faces toward V1. It was previously speculated that V1 and V2 are included in variable loops which form a canonical binding interface of TRIM and other protein families with the SPRY domain (James et al., 2007). A substitution involving P is expected to affect local backbone conformation, and a P-to-S substitution in particular results in an additional hydrogen bond donor–acceptor. Overall these findings indicate that position 385 is located at a putative binding site, where a P-to-S substitution is expected to affect the local structure and surface chemistry. This is consistent with the observed impact of these substitutions on TRIM5 $\alpha$  anti-HIV-2 activity. Nevertheless, it is not yet clear how these substitutions affect TRIM5 $\alpha$  restriction activity and binding affinity in particular, which calls for further investigation of the protein interactions involving TRIM5 $\alpha$ .

## Discussion

We previously reported that chimeric TRIM5 $\alpha$  containing baboon V1 could restrict HIV-2 GH123/Q that was not restricted by cynomolgus monkey TRIM5 $\alpha$  (Kono et al., 2008). Since baboons are reportedly sensitive to HIV-2 infection, there was a discrepancy between the ability of baboon TRIM5 $\alpha$  V1 to restrict HIV-2 and the susceptibility of host to virus. In the study presented here, we showed that the anti-HIV-2 activities of full-length baboon TRIM5 $\alpha$  and chimeric TRIM5 $\alpha$  containing the entire baboon SPRY domain were weaker than that of chimeric TRIM5 $\alpha$  containing baboon V1 alone, and that the full-length baboon TRIM5 $\alpha$  and chimeric TRIM5 $\alpha$  containing the entire baboon SPRY domain failed to restrict HIV-2 GH123/Q in CEM-SS cells. These results were consistent with those of the previous *in vivo* studies (Barnett et al., 1994; Locher et al., 1998, 2001). We also found that a single amino acid in V2 of the SPRY domain of TRIM5 $\alpha$  affected its anti-HIV-2 activity.

There are several precedents that a single amino acid change in V1 and V3 of the SPRY domain of TRIM5 $\alpha$  affects its restriction activity against retroviruses (Stremlau et al., 2005; Yap et al., 2005; Peron et al., 2006). A previous study comparing orangutan and gorilla TRIM5 $\alpha$ s showed that the amino acid residues at the 385th and 389th positions (corresponding to the 389th and 393rd positions of baboon TRIM5 $\alpha$ , the second and third boxes, respectively, indicated by white arrows in Fig. 7) in V2 of the SPRY domain of orangutan TRIM5 $\alpha$  are important

Cynomolgus monkey	378:	CAGFQSDAMCNIEQEN	:394	
Rhesus monkey	380:	.....Y.....	:396	
Baboon	380:	.....P.....	:396	
Orangutan	376:	.....P.....	:392	
Gorilla	376:	.....P..T...K...	:392	

**Fig. 7.** Alignment of amino acid sequences of V2 within the SPRY domain of cynomolgus monkey, rhesus monkey, baboon, orangutan, and gorilla TRIM5 $\alpha$ s. The first box indicated by the black arrow denotes the amino acid residue that affects anti-HIV-2 activity. The second and third boxes indicated by white arrows denote the amino acid residues that are important for anti-HIV-1 and anti-SIVmac activity of orangutan TRIM5 $\alpha$ .

for inhibiting HIV-1 and SIVmac (Ohkura et al., 2006). Ours is the first report to demonstrate the importance of another amino acid residue at the 385th (baboon) or 383rd (cynomolgus monkey) position in V2 of the SPRY domain of TRIM5 $\alpha$  (the first box indicated by a black arrow in Fig. 7) for restricting HIV-2. A structural model of the baboon TRIM5 $\alpha$  SPRY domain revealed that this 385th amino acid residue located near V1, the major determinant of species-specific viral restriction of TRIM5 $\alpha$ . In contrast to baboon and cynomolgus monkey TRIM5 $\alpha$ s, there was no evidence of an obvious contribution by the 385th amino acid residue for anti-HIV-2 activity in the case of rhesus monkey TRIM5 $\alpha$  background. It was reported that the specific combination of amino acids in V1 and V2 plays an important role in determining specificity of restriction (Ohkura et al., 2006). Therefore, it is possible that the combination of amino acids in V1 and V2 of the SPRY domain of baboon as well as cynomolgus monkey TRIM5 $\alpha$  is more stringent in its anti-HIV-2 activity than that of rhesus monkey TRIM5 $\alpha$ .

We showed that anti-HIV-2 activity of CBC chimeric TRIM5 $\alpha$  was almost the same as that of CBB P385S TRIM5 $\alpha$ . The amino acid differences between CBC chimeric TRIM5 $\alpha$  and CBB P385S TRIM5 $\alpha$  in the SPRY domain were located at two amino acid positions at the 389th in V2 (the second box in Fig. 7) and at the 422nd in V3 (Fig. 1). This indicates that these amino acid substitutions did not affect the restriction activity of TRIM5 $\alpha$  against HIV-2, though the amino acid substitution at the former position of gorilla TRIM5 $\alpha$  was reported to affect its anti-SIVmac activity (Ohkura et al., 2006). This is another example that the effect of amino acid substitution at the specific position in V2 could vary among different species of TRIM5 $\alpha$ .

We observed that the CBB chimeric TRIM5 $\alpha$  only partially inhibited HIV-2 GH123 when we used CEM-SS cells, while it almost completely did so when we used MT4 cells. We also found that the CBB chimeric TRIM5 $\alpha$  failed to inhibit HIV-2 GH123/Q when we used CEM-SS cells, while it at least partially limited replication of HIV-2 GH123/Q when we used MT4 cells. The anti-viral effect of TRIM5 $\alpha$  was apparently weaker in CEM-SS cells than in MT4 cells, which was at least in part due to lower levels of TRIM5 $\alpha$  expression by SeV in CEM-SS cells than in MT4 cells. The reason for these lower expression levels is not clear, however. Since the levels of other proteins such as green fluorescence protein, TRIM22, and CCR5 expressed in CEM-SS cells by SeV were also low (data not shown), this is not specific to TRIM5 $\alpha$ . We confirmed that the SeV could infect MT4 and CEM-SS cells with the same efficiency (data not shown). The low levels of TRIM5 $\alpha$  expression in CEM-SS cells are therefore attributed to low efficiency in transcription or translation of the proteins expressed by SeV. When we used CEM-SS cells, the anti-HIV-2 GH123 activity of CBB TRIM5 $\alpha$  was weaker than that of cynomolgus monkey TRIM5 $\alpha$ . It is possible that baboon is sensitive to broader strains of HIV-2 than cynomolgus monkey.

Although we have clearly demonstrated that the full-length baboon TRIM5 $\alpha$  cannot inhibit HIV-2 GH123/Q in CEM-SS cells, it is still possible that genomic polymorphisms in baboon TRIM5 $\alpha$  could affect the sensitivity of baboons to HIV-2. In rhesus monkey TRIM5 $\alpha$  V1, there is a 339th–TFP–341st to Q polymorphism, which reduces the strength of anti-HIV-2 activity (Newman et al., 2006; Kono et al., 2008). It would be interesting to investigate whether baboons TRIM5 $\alpha$  have genomic polymorphism(s), which could alter the anti-viral activity.

## Materials and methods

### Cloning and expression of TRIM5 $\alpha$

Construction of cynomolgus monkey TRIM5 $\alpha$  carrying an HA tag at the C-terminus (CM-TRIM5 $\alpha$ -HA), rhesus monkey TRIM5 $\alpha$  carrying an HA tag at the C-terminus (Rh-TRIM5 $\alpha$ -HA), CBC chimeric TRIM5 $\alpha$  carrying an HA tag at the C-terminus (CBC chimeric TRIM5 $\alpha$ -HA), RBR chimeric TRIM5 $\alpha$  carrying an HA tag at the C-terminus (RBR chimeric TRIM5 $\alpha$ -HA), CM SPRY(–) TRIM5 $\alpha$ , and CC(–) TRIM5 $\alpha$  were described previously (Nakayama et al., 2005; Song et al., 2007; Kono

et al., 2008; Maegawa et al., 2008). To obtain the C-terminal portion of baboon TRIM5 $\alpha$  fused with an HA tag (BamH I to Not I), we performed site-directed mutagenesis by using the PCR-mediated overlap primer extension method (Ho et al., 1989). Briefly, two DNA fragments with overlapping ends were generated by using the outer primers and the complementary primers with overlapping complementary nucleotides containing the desired mutations. The resultant two fragments were then combined in the subsequent fusion reaction to anneal the overlapping ends. This allows the 3' overlap of each strand to serve as a primer for a 3' extension of the complementary strand. Cloned RBR chimeric TRIM5 $\alpha$ -HA was used as a template for PCR-amplification with outer primers (5'-GCGGCCGCTACTATGGCTTCTGC-3' and 5'-GAATTCCTCAAGAGCTTGGTGA-3') and complementary primers (5'-GGCTTCCAACCTGATGCAATG-3' and 5'-CATTGCATCAGGTTGGAAGCC-3') containing nucleotides specific for baboon TRIM5 $\alpha$  (underlined). To generate CBB chimeric TRIM5 $\alpha$ , the previously generated C-terminal portion of baboon TRIM5 $\alpha$  fused with HA tag (BamH I to Not I) and the N-terminal portion of CBC chimeric TRIM5 $\alpha$  (Not I to BamH I) were assembled on the pcDNA3.1 (–) vector (Invitrogen, Carlsbad, CA). To generate CBB P385S TRIM5 $\alpha$ , the N-terminal portion of CBC chimeric TRIM5 $\alpha$  (Not I to BamH I) and the C-terminal portion of Rh-TRIM5 $\alpha$ -HA (BamH I to Not I) were assembled on the pcDNA3.1 (–) vector.

To generate mutant rhesus monkey TRIM5 $\alpha$ , in which an amino acid residue S at the 385th position was replaced with an amino acid P found in baboon TRIM5 $\alpha$  (Rh S385P TRIM5 $\alpha$ ), the N-terminal portion of rhesus monkey TRIM5 $\alpha$  (Not I to BamH I) and the C-terminal portion of CBB chimeric TRIM5 $\alpha$ -HA (BamH I to Not I) were assembled on the pcDNA3.1 (–) vector. Mutant cynomolgus monkey TRIM5 $\alpha$ , in which an amino acid residue S at the 383rd position was replaced with an amino acid P (CM S383P TRIM5 $\alpha$ ), was generated by site-directed mutagenesis with the PCR-mediated overlap primer extension method as described above. To obtain the BamH I–Not I fragment of CM S385P TRIM5 $\alpha$ , cloned cynomolgus monkey TRIM5 $\alpha$  was used as a template for PCR-amplification with the outer and complementary primers specified above. The resultant fragment and the N-terminal of cynomolgus monkey TRIM5 $\alpha$  (Not I and BamH I) were assembled on the pcDNA3.1 (–) vector.

Full-length baboon TRIM5 $\alpha$  (BBB TRIM5 $\alpha$ ) was generated by the site-directed mutagenesis. To obtain the N-terminal portion, we performed seven successive PCR reactions by using cloned rhesus monkey and cynomolgus monkey TRIM5 $\alpha$ s as templates. The primers used in these reactions are Not-TRIM primer (5'-GCGGCCGCTACTATGGCTTCTGC-3'), B1For primer (5'-CCTGAGTCTGCCCTGCCGCCACA-GCTTCTGCCAAGCGTGCATCACTGCGAACACAGGAAGTCCATGC-3'), B1Rev primer (5'-GCATGGACTTCTGTGGTTCGAGTATGCACGCTTGG-CAGAAGCTGTGGCCGAGGGCAGACTCAGG-3'), B2For primer (5'-CCAGAAGAGGGACTGAAGGTTGATCACTGTGC-3'), B2Rev primer (5'-GCACAGTGATCAACCTTCAGTCCCTCTCTGG-3'), B3For primer (5'-GAGAGACTCATCTCAGATCTGGAGC-3'), B3Rev primer (5'-GCTCCAGATCTGAGATGAGCTCTCTC-3'), and B4Rev primer (5'-GCATGCCAAATGTTGTTGGAGCCAGTGTACATCAACCCAGTAGCGTCGGA-CATCTGTTAGC-3') containing nucleotides specific for baboon TRIM5 $\alpha$  (underlined). The first PCR reaction was performed by using rhesus monkey TRIM5 $\alpha$  as a template and Not-TRIM and B1Rev as primers. The second reaction was performed by using rhesus monkey TRIM5 $\alpha$  as a template and B1For and B2Rev as primers. The resultant fragments were used as templates in the third PCR reaction with Not-TRIM and B2Rev as primers. The fourth reaction was performed by using rhesus monkey TRIM5 $\alpha$  as a template and B2For and B3Rev as primers. The resultant fragments were used as templates in the fifth reaction with Not-TRIM and B3Rev as primers. The sixth reaction was performed by using cynomolgus monkey TRIM5 $\alpha$  as a template and B3For and B4Rev as primers. The fifth and sixth fragments were used as templates in the seventh reaction with Not-TRIM and B4 Rev as primers. The resultant fragment and the C-terminal of CBB TRIM5 $\alpha$  (Sph I and Not I) were assembled on the

pcDNA3.1 (–) vector. To generate mutant baboon TRIM5 $\alpha$  (BBB P385S TRIM5 $\alpha$ ), the N-terminal portion of BBB TRIM5 $\alpha$  (Not I and BamH I) and the C-terminal portion of rhesus monkey TRIM5 $\alpha$  (BamH I and Not I) were assembled on the pcDNA3.1 (–) vector. The entire coding sequences of those TRIM5 $\alpha$ s were verified and then transferred to the Not I site of pSeV18b+. Recombinant SeVs carrying various TRIM5 $\alpha$ s were recovered with a previously described method (Nakayama et al., 2005). The viruses were passaged twice in embryonated chicken eggs and used as stock for all experiments.

#### Viral infection

$2 \times 10^5$  MT4 or CEM-SS cells were infected with SeV expressing each of the TRIM5 $\alpha$ s at a multiplicity of infection of 10 plaque-forming units per cell and incubated at 37 °C for 9 h. Cells were then superinfected with 20 ng of p25 from HIV-2 GH123, or GH123/Q strains. The culture supernatants were collected periodically, and the level of p25 was measured with a RETROtek antigen ELISA kit (ZeptoMetrix, Buffalo, NY).

#### Statistical analysis

Differences in relative p25 levels to control CM SPRY(–) TRIM5 $\alpha$  among chimeric TRIM5 $\alpha$ s were evaluated by *t*-test.

#### Western blot analysis

MT4 or CEM-SS cells infected with recombinant SeVs expressing HA tagged TRIM5 $\alpha$  proteins were lysed in lysis buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1% Nonident P40, 0.5% sodium deoxycholate). TRIM5 $\alpha$  proteins in the lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins in the gel were then electronically transferred to a membrane (Immobilion; Millipore, Billerica, MA). Blots were blocked and probed with anti-HA high affinity rat monoclonal antibody (Roche, Indianapolis, IN) and anti-actin affinity rabbit polyclonal antibody (Sigma, St. Louis, MO) overnight at 4 °C. Blots were then incubated with peroxidase-conjugated anti-rat IgG (American Qualex, San Clemente, CA) and peroxidase-linked protein A (Amersham, Piscataway, NJ), and bound antibodies were visualized with a Chemilumi-One chemiluminescent kit (Nacalai Tesque, Kyoto, Japan).

#### Modeling

Three protein domain structures were used as the templates for building the model: SPRY domains 2VOK and 2VOL of mouse TRIM21 (Keeble et al., 2008) and the human PRYSPTY domain 2FBE (Gruetter et al., 2006). To adjust the alignment for the variable positions of the TRIM5 $\alpha$  SPRY domain in primates, five other primate TRIM5 $\alpha$  SPRY domain sequences were used: human (NCBI accession number AK027593), african green monkey (AB210050), cynomolgus monkey (AB210052), rhesus monkey (AY523632) and sooty mangabey (AY710303, EF551344). Alignment of the baboon and other primate SPRY domain sequences to the three templates was obtained with the T-Coffee method (Notredame et al., 2000). Two additional methods (Edgar, 2004; Thompson et al., 1994) have also been used to generate multiple sequence alignments. Comparison of the alignments generated by the three methods revealed only minor differences. In particular, the three alignments differ by a shift of two to three positions in the placement of four insertions in the primate SPRY domain relative to the template sequences. This indicates that the alignment is reliable except in the regions of these four insertions since other parts of the sequences are aligned in the same manner independently of the method used. The model was built using Modeller 9v4 (Eswar et al., 2006; <http://salilab.org/modeller>) and visualized with PyMol v1.0r2 (DeLano WL, <http://www.pymol.org>).

### TRIM5 $\alpha$ cDNA sequences

TRIM5 $\alpha$  cDNA sequences for baboon (AY843505), orangutan (DQ437601), and gorilla (DQ4307600) were obtained from the GenBank database.

### Acknowledgments

The authors would like to thank Haihan Song for helpful discussions, Setsuko Bandou and Noriko Teramoto for their assistance and Thomas Lengauer for his support. This work was supported by grants from the Human Health Foundation, the Ministry of Education, Culture, Sports, Science, and Technology, and the Ministry of Health, Labor and Welfare, Japan.

### References

- Agy, M.B., Frumkin, L.R., Corey, L., Coombs, R.W., Wolinsky, S.M., Koehler, J., Morton, W.R., Katze, M.G., 1992. Infection of *Macaca nemestrina* by human immunodeficiency virus type-1. *Science* 257, 103–106.
- Arthur, L.O., Bess Jr., J.W., Waters, D.J., Pyle, S.W., Kelliher, J.C., Nara, P.L., Krohn, K., Robey, W.G., Langlois, A.J., Gallo, R.C., Fischinger, P.J., 1989. Challenge of chimpanzees (*Pan troglodytes*) immunized with human immunodeficiency virus envelope glycoprotein gp120. *J. Virol.* 63, 5046–5053.
- Barnett, S.W., Murthy, K.K., Herndier, B.G., Levy, J.A., 1994. An AIDS-like condition induced in baboons by HIV-2. *Science* 266, 642–646.
- Brennan, G., Kozyrev, Y., Kodama, T., Hu, S.L., 2007. Novel TRIM5 isoforms expressed by *Macaca nemestrina*. *J. Virol.* 81, 12210–12217.
- Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 32, 1792–1797.
- Eswar, N., Marti-Renom, M.A., Webb, B., Madhusudhan, M.S., Eramian, D., Shen, M., Pieper, U., Sali, A., 2006. Comparative protein structure modeling with modeller. *Curr. Protoc. Bioinform.* 5.6.1–5.6.30.
- Gruetter, C., Briand, C., Capitani, G., Mittl, P.R., Papin, S., Tschoopp, J., Gruetter, M.G., 2006. Structure of the PRYSPRY-domain: implications for autoinflammatory diseases. *FEBS Lett.* 580, 99–106.
- Hahn, B.H., Shaw, G.M., De Cock, K.M., Sharp, P.M., 2000. AIDS as a zoonosis: scientific and public health implications. *Science* 287, 607–614.
- Hatzioannou, T., Perez-Caballero, D., Yang, A., Cowan, S., Bieniasz, P.D., 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5 $\alpha$ . *Proc. Natl. Acad. Sci. U.S.A.* 101, 10774–10779.
- Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K., Pease, L.R., 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene* 77, 51–59.
- James, L.C., Keeble, A.H., Khan, Z., Rhodes, D.A., Trowsdale, J., 2007. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. *Proc. Natl. Acad. Sci. U. S. A.* 104, 6200–6205.
- Kecksova, Z., Ylinen, L.M., Towers, G.J., 2004. The human and African green monkey TRIM5 $\alpha$  genes encode Ref1 and Lv1 retroviral restriction factor activities. *Proc. Natl. Acad. Sci. U.S.A.* 101, 10780–10785.
- Keeble, A.H., Khan, Z., Forster, A., James, L.C., 2008. Trim21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. *Proc. Natl. Acad. Sci. U. S. A.* 105, 6045–6050.
- Kono, K., Song, H., Shingai, Y., Shioda, T., Nakayama, E.E., 2008. Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5 $\alpha$ s against human immunodeficiency virus type 2 infection. *Virology* 373, 447–456.
- Locher, C.P., Blackburn, D.J., Castro, B.A., Brasky, K.M., Levy, J.A., 1996. Susceptibility of peripheral blood mononuclear cells from gorillas, orangutans and baboons to diverse HIV isolates. *AIDS* 10, 1438–1440.
- Locher, C.P., Barnett, S.W., Herndier, B.G., Blackburn, D.J., Reyes-Teran, G., Murthy, K.K., Brasky, K.M., Hubbard, G.B., Reinhart, T.A., Haase, A.T., Levy, J.A., 1998. Human immunodeficiency virus-2 infection in baboons is an animal model for human immunodeficiency virus pathogenesis in humans. *Arch. Pathol. Lab. Med.* 122, 523–533.
- Locher, C.P., Witt, S.A., Herndier, B.G., Tenner-Racz, K., Racz, P., Levy, J.A., 2001. Baboons as an animal model for human immunodeficiency virus pathogenesis and vaccine development. *Immunol. Rev.* 183, 127–140.
- Lusso, P., Markham, P.D., Ranki, A., Earl, P., Moss, B., Dorner, F., Gallo, R.C., Krohn, K.J., 1988. Cell-mediated immune response toward viral envelope and core antigens in gibbon apes (*Hylobates lar*) chronically infected with human immunodeficiency virus-1. *J. Immunol.* 141, 2467–2473.
- Maegawa, H., Nakayama, E.E., Kuroishi, A., Shioda, T., 2008. Silencing of tripartite motif protein (TRIM) 5 $\alpha$  mediated anti-HIV-1 activity by truncated mutant of TRIM5 $\alpha$ . *J. Virol. Methods* 151, 249–256.
- Nakayama, E.E., Miyoshi, H., Nagai, Y., Shioda, T., 2005. A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5 $\alpha$  determines species-specific restriction of simian immunodeficiency virus SIVmac infection. *J. Virol.* 79, 8870–8877.
- Nakayama, E.E., Maegawa, H., Shioda, T., 2006. A dominant-negative effect of cynomolgus monkey tripartite motif protein TRIM5 $\alpha$  on anti-simian immunodeficiency virus SIVmac activity of an African green monkey orthologue. *Virology* 350, 158–163.
- Newman, R.M., Hall, L., Connole, M., Chen, G.L., Sato, S., Yuste, E., Diehl, W., Hunter, E., Kaur, A., Miller, G.M., Johnson, W.E., 2006. Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5 $\alpha$ . *Proc. Natl. Acad. Sci. U. S. A.* 103, 19134–19139.
- Notredame, C., Higgins, D.G., Heringa, J., 2000. T-Coffee: a novel method for fast and accurate multiple sequence alignment. *J. Mol. Biol.* 302, 205–217.
- Ohkura, S., Yap, M.W., Sheldon, T., Stoye, J.P., 2006. All three variable regions of the TRIM5 $\alpha$  B30.2 domain can contribute to the specificity of retrovirus restriction. *J. Virol.* 80, 8554–8565.
- Perez-Caballero, D., Hatzioannou, T., Yang, A., Cowan, S., Bieniasz, P.D., 2005. Human tripartite motif 5 $\alpha$  domains responsible for retrovirus restriction activity and specificity. *J. Virol.* 79, 8969–8978.
- Peron, M.J., Stremlau, M., Sodroski, J., 2006. Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5 $\alpha$ . *J. Virol.* 80, 5631–5636.
- Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., Messali, S., Cainarca, S., Guffanti, A., Minucci, S., Pellicci, P.G., Ballabio, A., 2001. The tripartite motif family identifies cell compartments. *EMBO J.* 20, 2140–2151.
- Sawyer, S.L., Wu, L.I., Emerman, M., Malik, H.S., 2005. Positive selection of primate TRIM5 $\alpha$  identifies a critical species-specific retroviral restriction domain. *Proc. Natl. Acad. Sci. U. S. A.* 102, 2832–2837.
- Song, H., Nakayama, E.E., Yokoyama, M., Sato, H., Levy, J.A., Shioda, T., 2007. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5 $\alpha$ s. *J. Virol.* 81, 7280–7285.
- Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., Sodroski, J., 2004. The cytoplasmic body component TRIM5 $\alpha$  restricts HIV-1 infection in Old World monkeys. *Nature* 427, 848–853.
- Stremlau, M., Perron, M., Welikala, S., Sodroski, J., 2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5 $\alpha$  determines the potency of human immunodeficiency virus restriction. *J. Virol.* 79, 3139–3145.
- Thompson, J.D., Higgins, D.G., Gibson, T.J., 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.* 22, 4673–4680.
- Yap, M.W., Nisole, S., Lynch, C., Stoye, J.P., 2004. Trim5 $\alpha$  protein restricts both HIV-1 and murine leukemia virus. *Proc. Natl. Acad. Sci. U. S. A.* 101, 10786–10791.
- Yap, M.W., Nisole, S., Stoye, J.P., 2005. A single amino acid change in the SPRY domain of human Trim5 $\alpha$  leads to HIV-1 restriction. *Curr. Biol.* 15, 73–78.

Research

Open Access

## Modification of a loop sequence between $\alpha$ -helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) *vif* and CA $\alpha$ -helices 4 and 5 loop improves replication in cynomolgus monkey cells

Ayumu Kuroishi<sup>1</sup>, Akatsuki Saito<sup>2</sup>, Yasuhiro Shingai<sup>1</sup>, Tatsuo Shioda<sup>1</sup>, Masako Nomaguchi<sup>3</sup>, Akio Adachi<sup>3</sup>, Hirofumi Akari<sup>2</sup> and Emi E Nakayama\*<sup>1</sup>

Address: <sup>1</sup>Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan, <sup>2</sup>Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Ibaraki 305-0843, Japan and <sup>3</sup>Department of Virology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima 770-8503, Japan

Email: Ayumu Kuroishi - kuroishi@biken.osaka-u.ac.jp; Akatsuki Saito - a-saito@nibio.go.jp; Yasuhiro Shingai - chokobo918@tcct.zaq.ne.jp; Tatsuo Shioda - shioda@biken.osaka-u.ac.jp; Masako Nomaguchi - nomaguchi@basic.med.tokushima-u.ac.jp; Akio Adachi - adachi@basic.med.tokushima-u.ac.jp; Hirofumi Akari - akari@nibio.go.jp; Emi E Nakayama\* - emien@biken.osaka-u.ac.jp

\* Corresponding author

Published: 3 August 2009

Received: 12 March 2009

Retrovirology 2009, 6:70 doi:10.1186/1742-4690-6-70

Accepted: 3 August 2009

This article is available from: <http://www.retrovirology.com/content/6/1/70>

© 2009 Kuroishi et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Human immunodeficiency virus type 1 (HIV-1) productively infects only humans and chimpanzees but not cynomolgus or rhesus monkeys while simian immunodeficiency virus isolated from macaque (SIVmac) readily establishes infection in those monkeys. Several HIV-1 and SIVmac chimeric viruses have been constructed in order to develop an animal model for HIV-1 infection. Construction of an HIV-1 derivative which contains sequences of a SIVmac239 loop between  $\alpha$ -helices 4 and 5 (L4/5) of capsid protein (CA) and the entire SIVmac239 *vif* gene was previously reported. Although this chimeric virus could grow in cynomolgus monkey cells, it did so much more slowly than did SIVmac. It was also reported that intrinsic TRIM5 $\alpha$  restricts the post-entry step of HIV-1 replication in rhesus and cynomolgus monkey cells, and we previously demonstrated that a single amino acid in a loop between  $\alpha$ -helices 6 and 7 (L6/7) of HIV type 2 (HIV-2) CA determines the susceptibility of HIV-2 to cynomolgus monkey TRIM5 $\alpha$ .

**Results:** In the study presented here, we replaced L6/7 of HIV-1 CA in addition to L4/5 and *vif* with the corresponding segments of SIVmac. The resultant HIV-1 derivatives showed enhanced replication capability in established T cell lines as well as in CD8<sup>+</sup> cell-depleted primary peripheral blood mononuclear cells from cynomolgus monkey. Compared with the wild type HIV-1 particles, the viral particles produced from a chimeric HIV-1 genome with those two SIVmac loops were less able to saturate the intrinsic restriction in rhesus monkey cells.

**Conclusion:** We have succeeded in making the replication of simian-tropic HIV-1 in cynomolgus monkey cells more efficient by introducing into HIV-1 the L6/7 CA loop from SIVmac. It would be of interest to determine whether HIV-1 derivatives with SIVmac CA L4/5 and L6/7 can establish infection of cynomolgus monkeys *in vivo*.

## Background

Human immunodeficiency virus type 1 (HIV-1) productively infects only humans and chimpanzees but not Old World monkeys (OWM) such as cynomolgus (CM) and rhesus (Rh) monkeys [1]. Unlike the simian immunodeficiency virus isolated from macaques (SIVmac), HIV-1 replication is blocked early after viral entry, before the establishment of a provirus in OWM cells [1-3]. This restricted host range of HIV-1 has greatly hampered its use in animal experiments and has caused difficulties for developing prophylactic vaccines and understanding HIV-1 pathogenesis. In order to establish a monkey model of HIV-1/AIDS, various chimeric viral genomes between SIVmac and HIV-1 (SHIV) have been constructed and tested for their replicative capabilities in simian cells. The first SHIV was generated on a genetic background of SIVmac with HIV-1 *tat*, *rev*, *vif*, and *env* genes [4]. Although such a SHIV is useful for the analysis of humoral immune responses against the Env protein [5-7], SHIVs containing other HIV-1 structural proteins, especially the Gag-Pol protein, have become highly desirable, since cellular immune response against Gag is generally believed to be important for disease control [8-10].

In recent years, several host factors involved in HIV-1 restriction in OWM cells have been identified. ApoB mRNA editing catalytic subunit (APOBEC) 3 G modifies the minus strand viral DNA during reverse transcription, resulting in an impairment of viral replication [11-13]. This activity could be counteracted with the viral protein Vif [14-17]. Although HIV-1 Vif can potently suppress human APOBEC3G, it is not effective against Rh APOBEC3G, which explains at least partly why HIV-1 replication is restricted in monkey cells. It is well known that Cyclophilin A (CypA) binds directly to the exposed loop between  $\alpha$ -helices 4 and 5 (L4/5) of HIV-1 capsid protein (CA), but not to the SIVmac CA. Several studies have found that CypA augments HIV-1 infection in human cells but inhibits its replication in OWM cells [18-20]. A construction of a SHIV with a minimal segment of SIVmac was reported recently by Kamada et al. [21]. This SHIV was designed to evade the restrictions mediated by APOBEC3G and CypA in OWM cells and contains the 7-aa segment corresponding to the L4/5 of CA and the entire *vif* of SIVmac. The SHIV was found to be able to replicate in primary CD4+ T cells from pig-tailed monkey as well as in the CM HSC-FT cell line. Both in HSC-F and in primary CD4+ T cells, this chimeric virus grew to lower titers than did SIVmac [21]; and when inoculated into pig-tailed monkeys, this SHIV did not cause CD4+ T cell depletion or any clinical symptoms in the inoculated animals [22]. Another SHIV, stHIV-1 (a virus carrying 202 amino acid residues of SIVmac CA and *vif* generated by Hatzioannou et al.) could replicate efficiently in Rh cells [23]. However, long-term passaging in Rh cells was necessary to generate

an efficiently replicating stHIV-1, and this adapted virus has not yet been fully characterized; so it may be that further modifications of the viral genome are necessary for optimal replication of HIV-1 genomes in OWM cells.

TRIM5 $\alpha$ , a member of the tripartite motif (TRIM) family proteins, was identified in 2004 as another intrinsic restriction factor of HIV-1 in OWM cells [24]. Rh and CM TRIM5 $\alpha$  were found to restrict HIV-1 but not SIVmac [25,26]. TRIM5 $\alpha$  recognizes the multimerized CA of an incoming virus by its  $\alpha$ -isoform specific SPRY domain [27-29] and is believed to be involved in innate immunity to control retroviral infection [30]. Previously, Ylinen et al. mapped one of the determinants of TRIM5 $\alpha$  sensitivity in L4/5 of HIV type 2 (HIV-2) CA [31]. In addition, we identified a single amino acid of the surface-exposed loop between  $\alpha$ -helices 6 and 7 (L6/7) of HIV-2 CA as a determinant of the susceptibility of HIV-2 to CM TRIM5 $\alpha$  [32]. We hypothesized that the L6/7 of HIV-1 CA also determines susceptibility to CM TRIM5 $\alpha$ . Here, we investigated whether an additional replacement of L6/7 of HIV-1 CA with that of SIVmac would enhance the replication capability of a SHIV genome in established T cell line HSC-F and in CD8+ cell depleted peripheral blood mononuclear cells (PBMCs) from CMs.

## Materials and methods

### DNA constructions

The HIV-1 derivatives were constructed on a background of infectious molecular clone NL4-3 [33]. NL-ScaVR, a virus containing SIVmac239 L4/5 and the entire *vif* gene, was constructed according to the procedure described by Kamada et al. [21]. A single amino acid His (H) at the 120th position of NL-ScaVR CA was replaced with Gln (Q) by means of site-directed mutagenesis with the PCR-mediated overlap primer extension method [34], and the resultant construct was designated NL-ScaVRA1. The L6/7 of CA (HNPPIP) of NL-SVR, NL-ScaVR, or NL-DT5R was also replaced with the corresponding segments of SIVmac239 CA (RQQNPIP) by means of site-directed mutagenesis, and the resultant constructs were designated NL-SVR6/7S, NL-ScaVR6/7S, or NL-DT5R6/7S, respectively. The BssHII-ApaI fragment of NL-ScaVR, NL-SVR6/7S, or NL-ScaVR6/7S, which corresponds to matrix (MA) and CA, was transferred to env deleted NL4-3 (NL-Nhe) to generate the env (-) version of each of the constructs.

### Cells and Virus propagation

The 293 T (human kidney), LLC-MK2 (Rh kidney), and TK-tsl3 (hamster kidney) adherent cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% heat-inactivated FBS. The CD4+ CXCR4+ CM T cell line HSC-F [35] was maintained in RPMI 1640 medium containing 10% FBS. Virus stocks were prepared by transfection of 293 T cells with HIV-1



NL4-3 derivatives using the calcium phosphate co-precipitation method. Viral titers were measured with the p24 or p27 RetroTek antigen ELISA kit (ZeptoMetrix, Buffalo, NY), and viral reverse transcriptase (RT) was quantified with the Reverse Transcriptase Assay kit (Roche Applied Science, Mannheim Germany).

#### **Green fluorescence protein (GFP) vector**

The HIV-1 vector expressing GFP was prepared as described previously [36,37]. To construct the HIV-1-WT-GFP and HIV-1-L4/5S-GFP vector, we replaced the Eco RI-Apa I fragment corresponding to MA and CA of the pMDLg/p.RRE packaging vector with those fragments from NL4-3 and NL-ScaVR, respectively. The GFP viruses were prepared from 293 T cells in a 15-cm dish by co-transfection with a combination of 24 µg of pMDLg/p.RRE derivatives, 36 µg of CS-CDF-CG-PRE (GFP encoding viral genomic plasmid), 10 µg of pMD.G (vesicular stomatitis virus glycoprotein (VSV-G) expressing plasmid), and 10 µg of pRSV-Rev (Rev expressing plasmid). Forty-eight hours after transfection, the culture supernatants were collected and used for infection.

#### **Viral infections**

$3 \times 10^5$  MT4 or HSC-F cells were infected with 20 ng of p24 of NL4-3, NL-ScaV, NL-ScaVR, NL-ScaVR6/7S, NL-DT5R, or NL-DT5R6/7S. The culture supernatants were collected periodically, and p24 levels were measured with an ELISA kit.

#### **Particle purification and Western blotting**

The culture supernatant of 293 T cells transfected with plasmids encoding HIV-1 NL4-3 derivatives was clarified by means of low speed centrifugation. Nine ml of the resultant supernatants were layered onto a 2 ml cushion of 20% sucrose (made in PBS) and centrifuged at 35,000 rpm for 2 h in a Beckman SW41 rotor. After centrifugation, the virion pellets were resuspended in PBS, and p24 antigen concentrations were measured with ELISA. SDS-polyacrylamide gel electrophoresis was applied to 120 ng of p24 of HIV-1 derivatives, and virion-associated proteins were transferred to a PVDF membrane. CA and CypA proteins were visualized with the anti-p24 antibody (Biodesign International, Saco, ME) and the anti-CypA antibody (Affinity BioReagents, Golden, CO), respectively.

#### **Saturation assay**

HIV-1 derivatives or SIVmac particles were prepared by transfecting each of the env-deleted HIV-1 NL4-3 derivatives or SIVmac plasmids with a plasmid encoding VSV-G into 293 T cells, and culture supernatants were collected two days after transfection. One day before infection, Rh LLC-MK2 and hamster TK-ts13 were plated at a density of  $5 \times 10^4$  cells per well in a 24-well plate. Prior to GFP virus

infection, the cells were pretreated for 2 hours with 200 ng of p24 of each of the HIV-1 or SIVmac particles pseudotyped with VSV-G. Immediately after the pre-treatment, the cells were washed and infected with the HIV-1-WT-GFP or HIV-1-L4/5S-GFP virus. Two hours after infection, the inoculated GFP viruses were washed, and the cells were cultivated in fresh media. Two days after infection, the cells were fixed by formaldehyde, and GFP expressing cells were counted with a flowcytometer. To suppress endogenous TRIM5 $\alpha$  activity, the cells were first infected with Sendai (SeV) expressing TRIM5 lacking the SPRY domain at a multiplicity of infection of 10 plaque forming units per cell. Sixteen hours after SeV infection, the cells were treated with 200 ng of p24 of the particles and then infected with the HIV-1-L4/5S-GFP vector as described above.


#### **Preparation of CD8-depleted CM PBMCs and viral infection**

CM PBMCs were suspended in RPMI medium 1640 supplemented with 10% (vol/vol) FBS, and the CD8+ cells were removed with a magnetic bead system (Miltenyi Biotec, Auburn, CA) and stimulated for 1 day with 1 µg/ml of PHA-L (Sigma, St. Louis, MO). For prolonged stimulation, CD8-depleted CM PBMCs were first stimulated with 1 µg/ml of PHA-L for 2 days and then with human IL2 100 U/ml for 2 more days.  $3 \times 10^5$  cells were then inoculated with 200 ng of p24 of NL-DT5R, NL-DT5R6/7S or with 200 ng of p27 of SIVmac239 and incubated at 37°C in a medium containing 100 U/ml of human IL2. The culture supernatants were collected periodically, and the levels of p24 or p27 were measured with an antigen capture assay (Advanced BioScience Laboratories, Kensington, MD)

## **Results**

#### **Construction and characterization of HIV-1 molecular clones containing CA and Vif sequences from SIVmac239**


Several proviral DNA constructs have been generated to counteract the restriction of HIV-1 replication in CM T cell line HSC-F [38] (Fig. 1). We first generated NL-SVR and NL-ScaVR according to the procedure described by Kamada et al. [21]. NL-ScaVR, a virus with SIVmac239 L4/5 CA and *vif*, could replicate slowly in HSC-F and replicated well in MT4 as previously reported (Fig. 2A). We recently discovered that the 120th amino acid of CA affected the sensitivity of HIV-2 to CM TRIM5 $\alpha$  [32]. We, therefore, introduced an additional amino acid substitution, His to Gln, at this position in NL-ScaVR. The resultant virus was designated NL-ScaVRA1; but this virus unexpectedly showed less efficient replication than did the parental NL-ScaVR in both MT4 and HSC-F cells (Fig. 2A), probably due to a reduced viral fitness created by this mutation. We, therefore, replaced the entire L6/7 CA of NL-ScaVR (HNPPIP) with the corresponding loop from SIVmac239 (RQQNPIP), and the resultant virus was des-



**Figure 1**  
**Structure of the chimeric HIV-1/SIVmac clones and a summary of their replication capabilities.** White bars denote HIV-1 (NL4-3) and gray bars SIVmac239 sequences. +++++, +++, ++, +, and - denote the peak titer of virus growth in human (Hu) and cynomolgus monkey (CM) cells, respectively, to more than 1000 ng/ml, 100–1000 ng/ml, 10–100 ng/ml, 1–10 ng/ml, and less than 1 ng/ml concentration of capsid (CA) protein in the culture supernatants. \* denotes that NL-DT5R6/7S replicated faster in HSC-F than did the parental NL-DT5R (see Fig. 2C).

ignated NL-ScaVR6/7S. The amount of RT per 1 ng of CA of NL-ScaVR (0.083 ng) was comparable to that of NL-ScaVR6/7S (0.081 ng), indicating that the replacement of L6/7 in HIV-1 with the corresponding loop of SIVmac did not affect the reactivity of CA antigen. Although NL-ScaVR6/7S grew slightly slower in MT4 cells, it could replicate more efficiently in HSC-F cells than the parental NL-ScaVR could (Fig. 2A). Similar results were obtained when we inoculated 20 ng of RT equivalent of NL-ScaVR or NL-ScaVR6/7S into HSC-F cells and measured the periodic RT production in culture supernatants (data not shown).

These findings demonstrated that L6/7 CA of SIVmac improved the replication in CM cells of an HIV-1 derivative that already contained a SIVmac L4/5 and *vif*. We then generated NL-SVR6/7S, in which the L4/5 sequence was from HIV-1, but the L6/7 and *vif* came from SIVmac. NL-SVR6/7S showed better replication than NL-ScaVR6/7S in MT4 cells, but lost its replicative capability in HSC-F cells (Fig. 2B). NL-SVR, a virus with SIVmac *vif*, could replicate in MT4, but failed to do so in HSC-F (Fig. 2B). These results indicated that both L4/5 and L6/7 of SIVmac are required for efficient replication in HSC-F.



**Figure 2**  
**Replication properties of HIV-1 derivatives.** Equal amounts of (A) NL-ScaVR (white diamonds: virus with SIVmac L4/5 and *vif*), and NL-ScaVRA1 (gray diamonds: virus with additional replacement of the 120th amino acid His with Gln in NL-ScaVR), and NL-ScaVR6/7S (black diamonds: virus with SIVmac L4/5, L6/7, and *vif*) (B) NL-SVR, NL-SVR6/7S, and NL-SVRS6/7S (gray diamonds: virus with SIVmac L6/7 and *vif*), and (C) NL-DT5R (white squares) and NL-DT5R6/7S (black squares), were inoculated into human MT4 or CM HSC-F cells, and culture supernatants were collected periodically. p24 antigen levels were measured by ELISA.


We then introduced SIVmac L6/7 into NL-DT5R, a molecularly cloned virus with two nonsynonymous changes in the *env* gene gained during long-term passages of NL-ScaVR in HSC-F cells [21]. The resultant virus was designated NL-DT5R6/7S. Although the peak titer of NL-DT5R6/7S was almost the same as that of NL-DT5R, NL-DT5R6/7S could replicate faster in HSC-F than the parental NL-DT5R (Fig. 2C). This finding confirmed that SIVmac L6/7 CA sequence improved the replication in CM cells of HIV-1 derivatives that contained SIVmac L4/5 and *vif*. The finding suggested that HIV-1 L6/7 and L4/5 CA sequences are important for intrinsic restriction in CM cells.

#### CypA incorporation into virus particles was not affected by replacement of HIV-1 L6/7 with that of SIVmac

Several studies have demonstrated that CypA augments HIV-1 infection in human cells [39], but inhibits its replication in OWM cells [18-20]. CypA was packaged in HIV-1 but not in SIVmac virus particles. To determine whether the replacement of HIV-1 L6/7 with that of SIVmac affects CypA binding of HIV-1 CA, we performed Western blot analysis of viral particles from HIV-1 derivatives. As shown in Fig. 3 (upper panel), CypA proteins were clearly detected in the NL-SVR particles (lane 1) but not in those of NL-ScaVR (lane 3), thus confirming that the L4/5 sequence of HIV-1 but not of SIVmac is required for CypA incorporation into viral particles. CypA proteins were detected in NL-SVR6/7S (lane 2) but not in NL-ScaVR6/7S (lane 4), indicating that the additional replacement of HIV-1 L6/7 with that of SIVmac had little effect on CypA incorporation. This finding suggests that the effect of L6/7 replacement on viral growth was independent from CypA binding of HIV-1 CA. When we used anti-p24 antibody (Fig. 3, lower panel), p55 Gag precursors and p24 proteins were clearly detected. There were no differences in the amount of p24 or the ratio of p24 to p55 among the four HIV-1 derivatives, indicating that the HIV-1 Gag precursor proteins with SIVmac L4/5 and L6/7 were processed normally by the viral protease.


#### Replacement of both L4/5 and L6/7 of HIV-1 CA with the corresponding loops from SIVmac impaired the CA binding activity of TRIM5 in Rh cells

It is known that the intrinsic restriction factors working against HIV-1 in CM and Rh cells can be saturated by inoculation of a high dose of HIV-1 particles [19,40-42]. To determine whether alteration in the CA of HIV-1 would affect its ability to saturate restriction factors, Rh LLC-MK2 cells were pre-treated with equal amounts of VSV-G pseudotyped HIV-1 particles that were with or without SIVmac L4/5 and/or L6/7 CA to saturate intrinsic restriction factor(s). The pre-treated cells were then infected with GFP-expressing HIV-1 carrying SIVmac L4/5 CA (HIV-1-L4/5S-GFP), since we wanted to exclude any effects of CypA on



**Figure 3**  
**Western blot analysis of CA and CypA in particles of HIV-1 derivatives.** The viral particles of NL-SVR (lane 1), NL-SVR6/7S (lane 2), NL-ScaVR (lane 3) and NL-ScaVR6/7S (lane 4) were purified by ultracentrifugation through a 20% sucrose cushion. CypA (upper panel) and p24 and p55 proteins (lower panel) were visualized by Western blotting (WB) using anti-CypA and anti-p24 antibody, respectively. "H" and "S" denote the amino acid sequences derived from HIV-1 and SIVmac, respectively.

the GFP expressing virus in LLC-MK2 cells. The susceptibility of particle-treated cells to virus infection was determined by the percentage of GFP-positive cells. The cells treated with the wild type (WT) particles showed greatly enhanced susceptibility to HIV-1 infection compared with non-treated cells (Fig. 4A, left), demonstrating that the intrinsic restriction factor(s) in LLC-MK2 cells were saturated by a high dose of particles. The cells treated with the particles carrying SIVmac L4/5 and those treated with particles carrying SIVmac L6/7 also showed enhanced susceptibility to HIV-1 infection (Fig. 4A, left). The cells treated with particles carrying both SIVmac L4/5 and L6/7 showed only slight enhancement of HIV-1 susceptibility (Fig. 4A, left;  $p = 0.007$  compared by means of paired t test using all data points with the WT particle treated cells). Similarly, the cells treated with SIVmac particles showed only minor enhancement in HIV-1 susceptibility (Fig. 4A, left). Hamster TK-ts13 cells which lack TRIM5 $\alpha$  expres-

**Figure 4**

**Saturation of intrinsic antiviral factors resulting from inoculation of high dose of virus particles.** (A) Rhesus LLC-MK2 cells or hamster TK-ts13 cells were pre-treated with equal amounts of VSV-G pseudotyped particles with WT HIV-1 (white squares: Wt), with SIVmac L4/5 (white triangles: 4/5S), with SIVmac L6/7 (white circles: 6/7S), with SIVmac L4/5 and L6/7 (white diamonds: 4/5S6/7S), with SIVmac239 (pluses: SIVmac) or none (crosses) for 2 hours. The cells were then infected with the GFP expressing HIV-1 vector carrying SIVmac L4/5 (A: HIV-1-L4/5S-GFP) or GFP expressing HIV-1 vector with WT capsid (B: HIV-1-WT-GFP). Representative data of four independent experiments are shown. (C) Saturation activities were assessed in the presence or absence of functional TRIM5 $\alpha$ . Before particle treatment, cells were infected with Sendai virus (SeV) expressing TRIM5 without the SPRY domain (black symbols), or an empty vector, parental Z strain of SeV (white symbols). Sixteen hours after SeV infection, cells were treated with particles for 2 hours and then infected with HIV-1-L4/5S-GFP. Representative data from six independent experiments are shown.

sion, on the other hand, showed no difference in HIV-1 susceptibility among cells treated with various HIV-1 derivatives or SIVmac particles (Fig. 4A, right). As shown in Fig. 4B, similar results were obtained when we used a GFP-expressing virus with WT HIV-1 capsid (HIV-1-WT-GFP). These results indicate that both HIV-1 L4/5 and L6/7 are important for CA binding to antiviral factor(s) in Rh cells. As described previously [20], HIV-1-WT-GFP could induce infection in only small numbers of LLC-MK2 cells. In contrast, more TK-ts13 cells were infected with HIV-1-WT-GFP than with HIV-1-L4/5-GFP. It is thus possible that CypA is a supporting factor for HIV-1 replication in hamster cells as well as in human cells.

Endogenous TRIM5 $\alpha$  seems to be a likely candidate for the antiviral factor saturated by a high dose of HIV-1 particles (Fig. 4A and 4B). To confirm this, we assessed the ability of WT and mutant HIV-1 particles to saturate the intrinsic restriction factor in the presence or absence of functional TRIM5 $\alpha$ . The dominant negative effect of an over-expressed TRIM5 mutant lacking SPRY domain [43] was used to suppress the function of cell endogenous TRIM5 $\alpha$ . As shown in Fig. 4C, the infection of a recombinant SeV expressing TRIM5 without the SPRY domain caused marked enhancement of HIV-1-L4/5S-GFP virus infection without prior particle treatment (crosses vs. asterisks). This indicates that this dominant negative


TRIM5 mutant successfully suppressed the restriction activity of endogenous TRIM5 $\alpha$ . Treatment with the WT HIV-1 particles also saturated the restriction factors in the cells infected with the empty vector virus (parental Z strain of SeV), while the additional effect of the dominant negative mutant TRIM5 $\alpha$  remained unclear (Fig. 4C left, white vs. black squares). These results suggest that the intrinsic factors saturated by the WT particles were mainly endogenous TRIM5 $\alpha$ . In contrast to the effect of the WT particle treatment, the effect of the dominant negative TRIM5 mutant on HIV-1 infection was evident when we used particles with SIVmac L4/5 and L6/7 (Fig. 4C, right, white vs. black diamonds,  $p = 0.007$ , paired t test). These findings suggest that the diminished capability of particles with SIVmac L4/5 and L6/7 to saturate restriction factors was mainly due to their loss of interaction with TRIM5 $\alpha$ . We, therefore, concluded that the ability of HIV-1 with SIVmac L4/5 and L6/7 to bind to TRIM5 $\alpha$  is diminished in LLC-MK2 cells.

#### HIV-1 derivative with SIVmac L4/5, L6/7, and vif sequences can replicate efficiently in monkey primary cells

To verify the effect of additional replacement of HIV-1 L6/7 with that of SIVmac in primary CM cells, we prepared PBMCs from CM and removed CD8 $^+$  cells by means of magnetic beads. The cells were then stimulated for 1 day with 1  $\mu$ g/ml of PHA-L. NL-DT5R6/7S showed more efficient replication than did the parental NL-DT5R in these cells and reached its peak titer 8 days after infection (Fig. 5A). For prolonged stimulation, CD8-depleted CM PBMCs were first stimulated with 1  $\mu$ g/ml of PHA-L for 2 days and then with human IL2 100 U/ml for 2 more days. In these cells, NL-DT5R with HIV-1 L6/7 did not grow at all. On the other hand, NL-DT5R with SIVmac L6/7 (NL-DT5R6/7S) grew in CM primary cells in response to prolonged stimulation by PHA and IL-2 to reach titers, similar to those attained in cells with short stimulation, up to 8 days after infection (Fig. 5A and 5B). Furthermore, NL-DT5R6/7S continued to grow to much higher titers and reached its peak titer 16 days after infection; this higher peak may be due to better proliferation of these cells than those cells receiving short term stimulation (Fig. 5B). These results confirmed that the replicative capability of HIV-1 in CM cells was augmented by the additional replacement of L6/7 of CA with the corresponding sequence from SIVmac.

#### Discussion

We created simian-tropic HIV-1 with more efficient replication capability in CM cells using the knowledge obtained from our previous study of TRIM5 $\alpha$  and HIV-2 capsid sequence variations [32]. Introduction of the entire SIVmac L6/7 CA into the previously constructed version of HIV-1 derivatives containing SIVmac L4/5 CA and vif [21] caused only a four amino acid change in CA but



**Figure 5**  
**Replication capabilities of HIV-1 derivatives in peripheral blood mononuclear cells (PBMC) from CM.** (A) PBMCs were obtained from CM, after which the CD8 $^+$  cells were removed, and the cells were stimulated with PHA-L for 1 day. (B) CD8-depleted CM PBMC were first stimulated with 1  $\mu$ g/ml of PHA-L for 2 days and then with human IL2 100 U/ml for 2 more days. Equal amounts of p24 of NL-DT5R (white squares) or NL-DT5R6/7S (black squares) were inoculated, and the culture supernatants were collected periodically. p24 antigen levels were measured by ELISA. Values represent means with actual fluctuations of duplicate samples added. The values for mock infected cell culture supernatants were zero in the ELISA assay.

showed improved replication capability of HIV-1 in the CM cell line HSC-F. Introduction of the entire SIVmac L6/7 CA into NL-DT5R, which has two additional amino acid mutations in the *env* gene, enhanced replication in CD8+ cells-depleted CM PBMCs. After prolonged stimulation of CM PBMCs, replication of the original version of NL-DT5R was suppressed while that of NL-DT5R with SIVmac L6/7 was not. It would thus be of interest to test whether those HIV-1 derivatives with both L4/5 and L6/7 from SIVmac can induce infection of CM *in vivo*.

While the high-dose inoculation of WT HIV-1 particles into Rh cells saturated endogenous TRIM5 $\alpha$  and enhanced subsequent infection with HIV-1, the introduction of HIV-1 particles that contained both L4/5 and L6/7 from SIVmac greatly impaired the ability of the particles to saturate TRIM5 $\alpha$ . When we replaced either HIV-1 L4/5 or L6/7 with the corresponding sequence from SIVmac, these particles still saturated TRIM5 $\alpha$ . These findings suggest that TRIM5 $\alpha$  recognized the overall structure composed of both L4/5 and L6/7 of HIV-1 CA. Our previous results from computational 3D-structure modeling analysis of HIV-2 CA support this hypothesis [32]. The 120th amino acid of HIV-2 CA, which affects viral susceptibility to TRIM5 $\alpha$  restriction, was located in L6/7. It is especially worth noting that the amino acid substitution at the 120th position was previously predicted to induce marked changes in the configuration of L6/7 and the L6/7 with the CM TRIM5 $\alpha$ -sensitive Pro positioned most closely to L4/5 of HIV-2 [32]. It would, therefore, be interesting to investigate whether monkey TRIM5 $\alpha$  proteins recognize CypA bound-L4/5 of HIV-1 CA.

During the preparation of our manuscript, Lin and Emerman reported that SIVagmTAN with both HIV-1 L4/5 and L6/7 was susceptible to Rh-TRIM5 $\alpha$  restriction [44]. Our result is consistent with their finding, since the HIV-1 particles with both SIVmac L6/7 and SIVmac L4/5 showed reduced saturation activity for TRIM5 $\alpha$  in Rh cells compared with HIV-1 particles with SIVmac L4/5 alone. Hatzioannou et al. very recently reported that stHIV-1 strains, which differ from HIV-1 only in the *vif* gene, could efficiently replicate in pig-tailed monkey and proposed a pig-tail monkey model of HIV-1 infection [45]. This is not surprising, since pig-tailed monkeys lack a TRIM5 $\alpha$  protein, and the dominant form of TRIM5 expressed in this monkey species is a TRIMCyp fusion protein lacking anti-HIV-1 activity [46-48].

When we subjected CD8-depleted CM PBMC to prolonged stimulation, NL-DT5R6/7S grew efficiently but NL-DT5R did not. Since the expression levels of TRIM5 $\alpha$  mRNA in human PBMC increased after stimulation with PHA and IL2 for 3 days (data not shown), we speculated that the higher expression levels of CM-TRIM5 $\alpha$  in fully

stimulated CM cells resulted in efficient restriction of NL-DT5R. However, no clear enhancement of CM TRIM5 $\alpha$  mRNA expression could be detected in the CM cells subjected to prolonged stimulation (data not shown). The reason why NL-DT5R failed to grow in CM cells with prolonged stimulation is not yet clear, but it is possible that fully stimulated CM cells exerted stronger intrinsic inhibitory activity against HIV-1 infection than those with short-term stimulation.

NL-DT5R6/7S and NL-ScaVR6/7S replicated less efficiently in human MT4 cells than did the parental NL-DT5R and NL-ScaVR. One possible explanation is that the virus with SIVmac L6/7 became resistant to CM TRIM5 $\alpha$  but became more sensitive to human TRIM5 $\alpha$ , since the latter can restrict SIVmac more efficiently than HIV-1. Another possibility is that replacement of CA allowed the virus to evade the intrinsic inhibitory factors in CM cells but impaired viral replication *per se*.

We used the CM T cell line HSC-F and CD8+ cell-depleted PBMC from CM but not from Rh for our replication experiments. Although we observed an improvement of viral replication in CM cells, we cannot assume that the replacement of L4/5 and L6/7 is enough for HIV-1 to replicate to high titers in Rh cells since the CM TRIM5 $\alpha$  resistant HIV-2 mutant virus GH123 (Q) was found to be restricted by Rh TRIM5 $\alpha$  [34]. NL-DT5R6/7S and NL-ScaVR6/7S also showed less efficient replication capability than did SIVmac (Fig. 1). We are currently trying to adapt these viruses to CM and Rh cells by means of long-term passaging in the hope of introducing compensating mutations that can overcome these disadvantages and further augment their replicative capabilities in human and simian cells to reach a similar level as seen with SIVmac.

## Conclusion

We have succeeded in improving simian-tropic HIV-1 for more efficient replication in CM cells by introduction of the SIVmac L6/7 CA sequence. It will be of interest to determine whether the HIV-1 derivatives with SIVmac L4/5 and L6/7 can induce infection in cynomolgus monkeys *in vivo*. Even if they fail to do so, further modification and/or adaptation of the current version of simian-tropic HIV-1 in monkey cells might be expected to lead to the development of an HIV-1 infection model in OWMs. This model has been long-awaited as a tool for vaccine development and as a model for better understanding of AIDS pathogenesis.

## Abbreviations

OWM: old world monkey; CM: cynomolgus monkey; Rh: rhesus monkey; SHIV: HIV-1/SIV chimeric virus; CypA: cyclophilin A; TRIM: tripartite motif; CA: capsid; PBMC: peripheral blood mononuclear cell; GFP: green fluores-

cence protein; VSV-G: vesicular stomatitis virus glycoprotein; SeV: Sendai virus; L4/5: a loop between  $\alpha$ -helices 4 and 5; L6/7: a loop between  $\alpha$ -helices 6 and 7.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

TS and EEN designed the research, AK, AS, YS, and EEN performed the research, TS, MN, AA, and EEN analyzed the data, and AA, HA, TS, and EEN wrote the paper.

### Acknowledgements

The authors wish to thank Mss. Setsuko Bandou and Noriko Teramoto for their helpful assistance.

This work was supported by grants from the Health Science Foundation, the Ministry of Education, Culture, Sports, Science, and Technology, and the Ministry of Health, Labour and Welfare, Japan.

### References

- Shibata R, Sakai H, Kawamura M, Tokunaga K, Adachi A: **Early replication block of human immunodeficiency virus type I in monkey cells.** *J Gen Virol* 1995, **76**(Pt 11):2723-2730.
- Himathongkham S, Luciw PA: **Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells.** *Virology* 1996, **219**:485-488.
- Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, Scammell J, Ferrigno P, Sodroski J: **Species-specific, postentry barriers to primate immunodeficiency virus infection.** *J Virol* 1999, **73**:10020-10028.
- Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A: **Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.** *J Virol* 1991, **65**:3514-3520.
- Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, Lewis MG: **Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.** *Nat Med* 2000, **6**:207-210.
- Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, Shibata R, Martin MA: **Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies.** *J Virol* 2002, **76**:2123-2130.
- Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, Willey R, Cho MW, Martin MA: **Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.** *Nat Med* 1999, **5**:204-210.
- Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA: **Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.** *J Virol* 1998, **72**:164-169.
- Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CV, Selig SM, Schwartz D, Sullivan J, Connors M: **HLA B\*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.** *Proc Natl Acad Sci USA* 2000, **97**:2709-2714.
- Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ: **HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.** *Nature* 1988, **336**:484-487.
- Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: **DNA deamination mediates innate immunity to retroviral infection.** *Cell* 2003, **113**:803-809.
- Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: **Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.** *Nature* 2003, **424**:99-103.
- Sheehy AM, Gaddis NC, Choi JD, Malim MH: **Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.** *Nature* 2002, **418**:646-650.
- Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR: **Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.** *Cell* 2003, **114**:21-31.
- Marin M, Rose KM, Kozak SL, Kabat D: **HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.** *Nat Med* 2003, **9**:1398-1403.
- Sheehy AM, Gaddis NC, Malim MH: **The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.** *Nat Med* 2003, **9**:1404-1407.
- Goila-Gaur R, Strebel K: **HIV-1 Vif, APOBEC, and intrinsic immunity.** *Retrovirology* 2008, **5**:51.
- Berthoux L, Sebastian S, Sokolskaja E, Luban J: **Lv1 inhibition of human immunodeficiency virus type I is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA.** *J Virol* 2004, **78**:11739-11750.
- Kootstra NA, Munk C, Tonnu N, Landau NR, Verma JM: **Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells.** *Proc Natl Acad Sci USA* 2003, **100**:1298-1303.
- Nakayama EE, Shingai Y, Kono K, Shioda T: **TRIM5alpha-independent anti-human immunodeficiency virus type I activity mediated by cyclophilin A in Old World monkey cells.** *Virology* 2008, **375**:514-520.
- Kamada K, Igarashi T, Martin MA, Khamsri B, Hachko K, Yamashita T, Fujita M, Uchiyama T, Adachi A: **Generation of HIV-1 derivatives that productively infect macaque monkey lymphoid cells.** *Proc Natl Acad Sci USA* 2006, **103**:16959-16964.
- Igarashi T, Iyengar R, Byrum RA, Buckler-White A, Dewar RL, Buckler CE, Lane HC, Kamada K, Adachi A, Martin MA: **Human immunodeficiency virus type I derivative with 7% simian immunodeficiency virus genetic content is able to establish infections in pig-tailed macaques.** *J Virol* 2007, **81**:11549-11552.
- Hatzioannou T, Princiotta M, Piatak M Jr, Yuan F, Zhang F, Lifson JD, Bieniasz PD: **Generation of simian-tropic HIV-1 by restriction factor evasion.** *Science* 2006, **314**:95.
- Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: **The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.** *Nature* 2004, **427**:848-853.
- Luban J: **Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type I infection.** *J Virol* 2007, **81**:1054-1061.
- Towers GJ: **The control of viral infection by tripartite motif proteins and cyclophilin A.** *Retrovirology* 2007, **4**:40.
- Li Y, Li X, Stremlau M, Lee M, Sodroski J: **Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection.** *J Virol* 2006, **80**:6738-6744.
- Nakayama EE, Miyoshi H, Nagai Y, Shioda T: **A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.** *J Virol* 2005, **79**:8870-8877.
- Ohkura S, Yap MW, Sheldon T, Stoye JP: **All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction.** *J Virol* 2006, **80**:8554-8565.
- Ozato K, Shin DM, Chang TH, Morse HC 3rd: **TRIM family proteins and their emerging roles in innate immunity.** *Nat Rev Immunol* 2008, **8**:849-860.
- Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ: **Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.** *J Virol* 2005, **79**:11580-11587.
- Song H, Nakayama EE, Yokoyama M, Sato H, Levy JA, Shioda T: **A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas.** *J Virol* 2007, **81**:7280-7285.



33. Adachi A, Gendelman HE, Koeing S, Folks T, Willey R, Rabson A, Martin MA: **Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.** *J Virol* 1986, **59**:284-291.
34. Kono K, Song H, Shingai Y, Shioda T, Nakayama EE: **Comparison of anti-viral activity of rhesus monkey and cynomolgus monkey TRIM5alphas against human immunodeficiency virus type 2 infection.** *Virology* 2008, **373**:447-456.
35. Akari H, Mori K, Terao K, Otani I, Fukasawa M, Mukai R, Yoshikawa Y: **In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus saimiri: its susceptibility to infection with simian immunodeficiency viruses.** *Virology* 1996, **218**:382-388.
36. Miyoshi H, Takahashi M, Gage FH, Verma IM: **Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector.** *Proc Natl Acad Sci USA* 1997, **94**:10319-10323.
37. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM: **Development of a self-inactivating lentivirus vector.** *J Virol* 1998, **72**:8150-8157.
38. Akari H, Fukumori T, Iida S, Adachi A: **Induction of apoptosis in Herpesvirus saimiri-immortalized T lymphocytes by blocking interaction of CD28 with CD80/CD86.** *Biochem Biophys Res Commun* 1999, **263**:352-356.
39. Lin TY, Emerman M: **Cyclophilin A interacts with diverse lentiviral capsids.** *Retrovirology* 2006, **3**:70.
40. Besnier C, Takeuchi Y, Towers G: **Restriction of lentivirus in monkeys.** *Proc Natl Acad Sci USA* 2002, **99**:11920-11925.
41. Cowan S, Hatzioannou T, Cunningham T, Muesing MA, Gottlinger HG, Bieniasz PD: **Cellular inhibitors with FvI-like activity restrict human and simian immunodeficiency virus tropism.** *Proc Natl Acad Sci USA* 2002, **99**:11914-11919.
42. Hatzioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ: **Restriction of multiple divergent retroviruses by Lvl and Ref1.** *Embo J* 2003, **22**:385-394.
43. Maegawa H, Nakayama EE, Kuroishi A, Shioda T: **Silencing of tripartite motif protein (TRIM) 5alpha mediated anti-HIV-1 activity by truncated mutant of TRIM5alpha.** *J Virol Methods* 2008, **151**:249-256.
44. Lin TY, Emerman M: **Determinants of cyclophilin A-dependent TRIM5 alpha restriction against HIV-1.** *Virology* 2008, **379**:335-341.
45. Hatzioannou T, Ambrose Z, Chung NP, Piatk M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD: **A macaque model of HIV-1 infection.** *Proc Natl Acad Sci USA* 2009, **106**:4425-4429.
46. Kuang YQ, Tang X, Liu FL, Jiang XL, Zhang YP, Gao G, Zheng YT: **Genotyping of TRIM5 locus in northern pig-tailed macaques (Macaca leonina), a primate species susceptible to Human Immunodeficiency Virus type 1 infection.** *Retrovirology* 2009, **6**:58.
47. Virgen CA, Kratovac Z, Bieniasz PD, Hatzioannou T: **Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species.** *Proc Natl Acad Sci USA* 2008, **105**:3563-3568.
48. Brennan G, Kozyrev Y, Kodama T, Hu SL: **Novel TRIM5 isoforms expressed by Macaca nemestrina.** *J Virol* 2007, **81**:12210-12217.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)



# Impact of novel TRIM5 $\alpha$ variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection

Toshiaki Nakajima<sup>a,b,\*</sup>, Emi E. Nakayama<sup>c,\*</sup>, Gurvinder Kaur<sup>d</sup>,  
Hiroshi Terunuma<sup>e</sup>, Jun-ich Mimaya<sup>f</sup>, Hitoshi Ohtani<sup>a,b</sup>,  
Narinder Mehra<sup>d</sup>, Tatsuo Shioda<sup>c</sup> and Akinori Kimura<sup>a,b</sup>

**Objective:** TRIM5 $\alpha$  is one of the factors contributing to intracellular defense mechanisms against HIV-1 infection. We investigated the association of TRIM5 $\alpha$  sequence variations with the susceptibility to HIV-1 infection in Japanese and Indian.

**Design:** Sequence variations in TRIM5 $\alpha$  were investigated in HIV-1-infected patients and ethnic-matched controls. Functional alterations caused by rare variants were analyzed.

**Methods:** We sequenced TRIM5 $\alpha$ -exon 2 in both Japanese (94 HIV-1-infected patients and 487 controls) and Indian (101 HIV-1-infected patients and 99 controls). Frequency of variants and haplotypes were compared between the HIV-1-infected patients and controls. Functional analyses were performed for two rare variants, Gly110Arg and G176del.

**Results:** The frequency of 43Tyr-allele in the Indian HIV-1-infected patients was significantly lower than that in the ethnic-matched controls (odds ratio=0.52, 95% confidence interval=0.31–0.89,  $P=0.015$ ). A similar tendency was observed in Japanese sample, although it was not statistically significant (odds ratio=0.67, 95% confidence interval=0.43–1.05,  $P=0.095$ ). On the other hand, haplotype analyses revealed that the haplotype carrying the 43Tyr-allele was significantly associated with the reduced susceptibility to HIV-1 infection in both ethnic groups. Functional analysis revealed that Gly110Arg variant weakened the anti-HIV-1 and anti-HIV-2 activities of human TRIM5 $\alpha$ , whereas the truncated G176del-TRIM5 enhanced the antiviral activity of coexpressed TRIM5 $\alpha$ . Epidemiological data were consistent in that Gly110Arg and G176del were associated with the susceptibility to and protection from HIV-1 infection, respectively.

**Conclusion:** Both common and rare variants of TRIM5 $\alpha$  are associated with the susceptibility to HIV-1 infection.

© 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

*AIDS* 2009, **23**:2091–2100

**Keywords:** association, HIV-1, polymorphism, susceptibility, TRIM5

<sup>a</sup>Department of Molecular Pathogenesis, Medical Research Institute, <sup>b</sup>Laboratory of Genome Diversity, Graduate School of Biomedical Science, Tokyo Medical and Dental University, Tokyo, <sup>c</sup>Department of Viral Infection, Research Institute for Microbial Disease, Osaka University, Osaka, Japan, <sup>d</sup>Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi, India, <sup>e</sup>Biotherapy Institute of Japan, Tokyo, and <sup>f</sup>Division of Hematology and Oncology, Shizuoka Children's Hospital, Shizuoka, Japan.

Correspondence to Akinori Kimura, MD, PhD, Department of Molecular Pathogenesis, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.

Tel: +81 3 5803 4905; fax: +81 3 5803 4907; e-mail: akitis@mri.tmd.ac.jp

\* T.N. and E.E.N. contributed equally to this study.

Received: 25 March 2009; revised: 22 July 2009; accepted: 29 July 2009.

DOI:10.1097/QAD.0b013e328331567a

## Introduction

Although the cellular and humoral immune systems are known to play crucial roles in the defense against retroviral infection, mammals have also evolved defense mechanisms within cells. Several lines of evidence indicated that restriction factors within host cells inhibit viral replication more effectively than the immune system, and TRIM5 $\alpha$  is one of the factors involved in the intracellular defense against retroviruses [1,2]. It was reported that TRIM5 $\alpha$  from rhesus monkeys restricted HIV-1 production at a postentry, preintegration stage in the viral life cycle through rapid degradation of HIV-1 Gag polyproteins [3,4], whereas human TRIM5 $\alpha$  restricted HIV-1 only weakly and potently restricted N-tropic murine leukemia virus [5,6].

TRIM5 is a member of the tripartite-motif containing superfamily and includes a Really Interesting New Gene (RING) domain, B-box 2 domain and coiled-coil domain [7]. Alternative splicing of TRIM5 gene generates several isoforms of TRIM5 proteins. One isoform, TRIM5 $\alpha$ , contains the carboxy-terminal B30.2 (SPRY) domain that is essential for anti-HIV-1 activity, and sequence differences in the SPRY domain contribute to the differences in the anti-HIV-1 activity among primate species [4,8–13].

It is well known that the infection by HIV-1 and progression to AIDS are variable among human individuals, which are considered to be controlled by diversity in the human genome [14,15]. As TRIM5 $\alpha$  has crucial roles in the restriction of viral replication within the host cells, it is a good candidate gene controlling the susceptibility to or protection from HIV-1 infection and/or progression to AIDS. Actually, several studies have demonstrated that common TRIM5 $\alpha$  functional polymorphisms, His43Tyr and Arg136Gln, were associated with the susceptibility to HIV-1 infection. However, the significance of association has not been established [16–20].

In this study, we investigated two ethnic populations, Japanese and Indian, for the polymorphism in TRIM5 $\alpha$ -exon 2 and its association with the HIV-1 infection. We found that a TRIM5 $\alpha$  haplotype carrying the 43Tyr-allele was associated with the reduced susceptibility to HIV-1 infection in both ethnic groups. In addition, we identified two rare variants, G176del and Gly110Arg, which affected the anti-HIV-1 activity and showed suggestive associations with the HIV-1 infection.

## Material and methods

### Participants

Protocol of the present study was approved by the Ethics Review Board of the Medical Research Institute, Tokyo

Medical and Dental University and that of All India Institute of Medical Science. At the set-up of the cohort in 1995, all the HIV-1-infected Japanese hemophiliac patients had been infected for longer than 10 years and they were asymptomatic without any antiviral measures. Blood samples were collected from 94 well characterized patients who were selected from the cohort after obtaining written informed consent [21,22]. Control DNA samples were prepared from Epstein–Barr virus-transformed human B cell lines established from randomly selected healthy donors with written informed consent ( $n=487$ ), which were purchased from the Japan Health Sciences Foundation. The DNA samples from HIV-1-infected individuals were prepared from the blood sample by using QuickGene DNA whole blood kit S (FUJIFILM, Tokyo, Japan). In addition, blood DNA samples were obtained with written informed consent from 101 HIV-1-infected Indian patients and 99 healthy Indian volunteers in the related hospitals of All India Institute of Medical Sciences, New Delhi. DNA samples from whites ( $n=96$ ) and African-Americans ( $n=96$ ) were obtained from the Coriell Institute for Medical Research (Camden, New Jersey, USA).

### Identification and genotyping of nucleotide variations in TRIM5 $\alpha$ -exon 2

Primer sets were designed to amplify the genomic segments covering the entire TRIM5 $\alpha$ -exon 2 as follows: sense primer (5'-TTGGTCCCATTTTAACC TTCC-3') and antisense primer (5'-AAGGCAGT TAA TGTCAAAGGC-3'). Genomic DNA was subjected to PCR amplification followed by sequencing on both strands using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, California, USA). Polymorphisms were identified using the Sequencher program (Gene Code Co., Ann Arbor, Michigan, USA).

### Cloning and expression of TRIM5 $\alpha$

The generation of recombinant Sendai viruses (SeVs) expressing human TRIM5 $\alpha$ , human/African green monkey (AGM) chimeric TRIM5 $\alpha$  [18], cynomolgus monkey TRIM5 $\alpha$  lacking SPRY domain [CM-TRIM5 $\alpha$ -SPRY(-)-HA] [23] and AGM TRIM5 $\alpha$  lacking coiled-coil domain [AGM-TRIM5 $\alpha$ -CC(-)-HA] has been described previously [24]. All TRIM5 $\alpha$  variants carried a hemagglutinin (HA)-tag (YPYDVP-DYAA) at the C-terminus. The Gly110Arg mutation was introduced into both human TRIM5 $\alpha$  and human/AGM chimeric TRIM5 $\alpha$  by PCR site-directed mutagenesis. To generate SeV expressing G176del carrying an HA-tag at the N-terminus (HA-G176del-TRIM5), the amplified PCR fragment from genomic DNA carrying G176del was cloned into a pSeV18+b(+) vector. Recombinant SeVs expressing human 110Arg-TRIM5 $\alpha$ , human/AGM chimeric 110Arg-TRIM5 $\alpha$  and HA-G176del-TRIM5 were recovered as described previously [12]. The second passages in embryonated

chicken eggs were used as the stock viruses in all experiments.

### Western blot analysis

MT4 cells ( $1 \times 10^6$ ) infected with recombinant SeVs expressing HA-tagged TRIM5 $\alpha$  proteins were lysed in lysis buffer (50 mmol/l Tris-HCl, pH 7.5, 150 mmol/l NaCl, 1% Nonidet P40, 0.5% sodium deoxycholate). Western blot analyses with anti-HA high-affinity rat monoclonal antibody (Roche, Indianapolis, Indiana, USA) and anti-CypA affinity rabbit polyclonal antibody (Sigma, St Louis, Missouri, USA) were performed as described previously [19].

### Viral infection

MT4 or CEM-SS cells ( $1 \times 10^5$ ) were infected with SeV expressing human TRIM5 $\alpha$ , human 110Arg-TRIM5 $\alpha$ , human/AGM chimeric TRIM5 $\alpha$ , human/AGM chimeric 110Arg-TRIM5 $\alpha$ , CM-TRIM5 $\alpha$ -SPRY(-) or AGM-TRIM5 $\alpha$ -CC(-) at a multiplicity of infection of 10 plaque-forming units (PFUs) per cell and incubated at 37°C for 9 h. To examine the effects of G176del-TRIM5 on the full length TRIM5 $\alpha$ , 5 PFU per cell of each SeV expressing either CM-TRIM5 $\alpha$ -SPRY(-), AGM-TRIM5 $\alpha$ -CC(-) or HA-G176del-TRIM5 was simultaneously inoculated to MT4 cells with SeV expressing human/AGM chimeric TRIM5 $\alpha$ . Cells were then superinfected with 30 ng of p24 of an X4 HIV-1 strain NL43 or 30 ng of p25 of HIV-2 GH123. The culture supernatants were collected periodically and the level of p24 or p25 was measured by RETROtek antigen ELISA kit (ZeptoMetrix, Buffalo, New York, USA).

### Statistical analysis

All statistical analyses in this study were performed using GraphPad InStat version 3.06 for Windows (GraphPad Software, San Diego, California, USA). Correction for multiple testing was done by multiplying the *P* value by the number of tested markers to obtain the corrected *P* (*P<sub>c</sub>*) value. Haplotype association analyses were performed by using SNPalyze version 6.0 standard (DYNACOM Co., Ltd., Tokyo, Japan). Meta-analysis was performed using a Mantel-Haenszel method. *P* values less than 0.05 were considered to be statistically significant.

## Results

### Associations of TRIM5 $\alpha$ -exon 2 polymorphism with susceptibility to HIV-1 infection

We identified 10 different nucleotide variations in the TRIM5 $\alpha$ -exon 2 in this study and eight of them were reported in previous studies. Most of the sequence variations, except for His43Tyr, Val112Phe and Arg136Gln were observed with low frequencies (allele

frequency less than 0.05) in the tested populations. Associations between the TRIM5 $\alpha$  polymorphisms and the susceptibility to HIV-1 infection were summarized in Table 1. The frequency of 43Tyr-allele in Indian HIV-1-infected patients was significantly lower than that in the ethnic-matched controls [odds ratio (OR) (95% confidence interval (CI)) = 0.52 (0.31–0.89), *P* = 0.015 by  $\chi^2$  test]. A similar tendency was observed in Japanese, although it did not reach statistical significance [OR (95% CI) = 0.67 (0.43–1.05), *P* = 0.095 by  $\chi^2$  test]. A meta-analysis of data from two populations demonstrated the significant association corrected for multiple testing [OR (95% CI) = 0.61 (0.43–0.85), *P* = 0.0004, *P<sub>c</sub>* = 0.004]. When we analyzed the data for HIV-1 loads after 7–8 years during the observation period, which were available for 75 Japanese HIV-1-infected patients, no significant correlation between the His43Tyr genotype and HIV-1 loads was observed (data not shown).

Two novel polymorphisms, Gly110Arg and G176del, were identified only in the Japanese samples. The Gly110Arg variant was more frequent in the HIV-1-infected patients than in the controls [OR (95% CI) = 13.12 (2.53–68.21), *P* = 0.002 by Fisher's exact test]. On the other hand, the G176del variant, a deletion of a G at the coding nucleotide position 176 from the initiation site of translation, which may result in a truncated TRIM5 protein product, was found only in the Japanese controls.

### TRIM5 $\alpha$ haplotype and susceptibility to HIV-1 infection

The associations between the susceptibility to HIV-1 infection and TRIM5 $\alpha$  haplotypes composed of five sequence variations with relatively high frequency, His43Tyr, Gly110Arg, Val112Phe, Thr128Thr and Arg136Gln, were investigated in Japanese and Indian populations (Table 2). In both populations, the frequency of a common haplotype 43Tyr-110Gly-112Val-128Thr-136Arg was significantly low in the HIV-1-infected patients. This result was consistent with the association of 43Tyr with the reduced susceptibility to HIV-1 infection, because this haplotype was in tight linkage disequilibrium with the 43Tyr-allele.

### Anti-HIV-1 activity of TRIM5 $\alpha$ was attenuated by Gly110Arg substitution

To investigate the functional significance of Gly110Arg on the anti-HIV activity of TRIM5 $\alpha$ , we constructed a SeV containing a C-terminal HA-tagged human 110Arg-TRIM5 $\alpha$  (Fig. 1a). As shown in Fig. 1b, expression level of variant 110Arg-TRIM5 $\alpha$  was comparable to that of wild-type human TRIM5 $\alpha$ . A human/AGM chimeric TRIM5 $\alpha$ , which possessed the SPRY domain of AGM TRIM5 $\alpha$ , was also generated to enhance the weak anti-HIV-1 activity of human TRIM5 $\alpha$  (Fig. 1a). As shown in Fig. 1b, the expression level of human/AGM chimeric